Results 21 to 30 of about 8,804 (200)

Cardiovascular disease in non-classic Pompe disease: A systematic review [PDF]

open access: yes, 2020
Pompe disease is a rare inherited metabolic and neuromuscular disorder, presenting as a spectrum, with the classic infantile form on one end and the more slowly progressive non-classic form on the other end.
Doorn, P.A. (Pieter) van   +7 more
core   +3 more sources

From the hypertransaminasemia symptoms to the recognition of late-onset Pompe disease in a 12-year-old boy

open access: yesPediatria Polska, 2021
The paper presents the case of a 12-year-old boy hospitalised due to persistent hypertransaminasemia of unknown origin, in whom rare metabolic disease – Pompe disease, was finally diagnosed.
Ewa Grzywna, Jarosław Kwiecień
doaj   +1 more source

ALGLUCOSIDASE ALFA — A NEW STAGE IN THE THERAPY OF INFANTILE POMPE DISEASE

open access: yesПедиатрическая фармакология, 2014
Pompe disease is a rare severe hereditary disease caused by excessive glycogen storage in organs and target tissues due to the acid α-glucosidase gene mutation.
E. N. Basargina   +2 more
doaj   +1 more source

Modeling CNS Involvement in Pompe Disease Using Neural Stem Cells Generated from Patient-Derived Induced Pluripotent Stem Cells

open access: yesCells, 2020
Pompe disease is a lysosomal storage disorder caused by autosomal recessive mutations in the acid alpha-glucosidase (GAA) gene. Acid alpha-glucosidase deficiency leads to abnormal glycogen accumulation in patient cells.
Yu-Shan Cheng   +7 more
doaj   +1 more source

Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease

open access: yesCommunications Biology, 2021
Wang et al. describe the development of a 3D in vitro model of human skeletal muscle that recapitulates the pathophysiology of Pompe disease. They further define a Pompe disease-specific transcriptional signature, confirm its presence in the Pompe ...
Jason Wang   +9 more
doaj   +1 more source

Precocious puberty in patients with Pompe disease [PDF]

open access: yes, 2023
[[abstract]]Introduction: The life expectancy of Pompe disease patients has increased due to improved neonatal screening and enzyme replacement therapy.
Tsai, MJM;Chen, MH;Chien, YH;Tung, YC
core   +2 more sources

Public support for neonatal screening for Pompe disease, a broad-phenotype condition

open access: yesOrphanet Journal of Rare Diseases, 2012
Background Neonatal screening for Pompe disease has been introduced in Taiwan and a few U.S. states, while other jurisdictions including some European countries are piloting or considering this screening. First-tier screening flags both classic infantile
Weinreich Stephanie   +8 more
doaj   +1 more source

Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient

open access: yesMolecular Therapy: Methods & Clinical Development, 2015
Pompe disease is an autosomal recessive inherited metabolic disease caused by deficiency of acid α-glucosidase (GAA). Glycogen accumulation is seen in the affected organ such as skeletal muscle, heart, and liver.
Yohei Sato   +8 more
doaj   +1 more source

Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus

open access: yesFrontiers in Neurology, 2021
Background: Pompe disease, also denoted as acid maltase or acid α-glucosidase deficiency or glycogen storage disease type II, is a rare, autosomal recessive lysosomal storage disorder.
Farzad Fatehi   +14 more
doaj   +1 more source

The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan

open access: yesInternational Journal of Neonatal Screening, 2020
Pompe disease Newborn screening (NBS) aims at diagnosing patients with infantile-onset Pompe disease (IOPD) early enough so a timely treatment can be instituted.
Shu-Chuan Chiang   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy